Rating Change
UBS reiterated its Neutral rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) on November 03, 2026.
reiterateNASDAQ:IOVA
UBS Reiterates Neutral Rating on Iovance Biotherapeutics, Inc. (IOVA)
UBS reiterated its Neutral rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) on November 03, 2026.
At publication ·
What changed
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) · reiterate
- Firm
- UBS
- Rating
- Neutral to Neutral
- Price at event
- $8.83
- Market capitalization
- $744.6M
At a glance
Key takeaways
- UBS maintained a Neutral rating on Iovance Biotherapeutics (IOVA) on November 3, 2026, while the stock trades at $8.83 with a $744.6M market cap.
- IOVA stock surged 311.3% over the past 52 weeks, significantly outpacing typical healthcare sector performance.
- Among 10 recent analyst ratings, 7 are Buy, 3 are Hold, and 0 are Sell, showing predominantly positive sentiment despite UBS's Neutral stance.
- Analyst ratings provide one input for investment decisions, though consensus recommendations have mixed predictive power on their own.
Market Context
Iovance Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $8.83 with a market capitalization of $744.6M. The stock has gained 311.3% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Iovance Biotherapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Iovance Biotherapeutics, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 03, 2026 | UBS | Neutral | N/A |
| Oct 13, 2026 | Barclays | Overweight | N/A |
| Oct 08, 2026 | Baird | Neutral | N/A |
| Sep 30, 2026 | Wells Fargo | Overweight | N/A |
| Sep 29, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IOVA Stock Page
Frequently Asked Questions
What does the Neutral rating mean for IOVA?
A rating of Neutral from UBS reflects the analyst's outlook on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IOVA forecast page.
Loading related coverage…